NPS RADAR

NPS RADAR provides health professionals with timely, independent evidence-based information on new drugs and medical tests and changes to listings on the Pharmaceutical Benefits Scheme.

NPS RADAR is print-published 3 times a year, in line with major updates to the Schedule of Pharmaceutical Benefits, so it is available around the time when new medicines can be prescribed or dispensed.

Our free NPS RADAR email alerts keep subscribers up to date with new drugs and medical tests as each new issue of NPS RADAR is released.

Latest issue

Brief item: Dapagliflozin (Forxiga) with insulin, an option for type 2 diabetes add-on treatment

From 1 April 2015 dapagliflozin will be the first sodium–glucose co-transporter-2 (SGLT2) inhibitor to be PBS listed for type 2 diabetes add-on treatment in dual combination with insulin.

Brief item: SGLT2 inhibitor listings: indications and combinations

Four recent changes to PBS listings for sodium–glucose co-transporter-2 (SGLT2) inhibitors will impact on second- and third-line treatments for type 2 diabetes.

Editorial: GP monitoring of specialist prescribed medicines

Many medicines are PBS listed for specialist prescribing only but, for some of these, GPs also need to be well informed. This issue of RADAR reviews two commonly prescribed ocular medicines, aflibercept (Eylea) and ranibizumab (Lucentis), used in the treatment of age-related macular degeneration, with an emphasis on factors of relevance for primary care health professionals.

Ranibizumab (Lucentis) and aflibercept (Eylea) for ocular indications

Expanded PBAC recommendations for these anti-vascular endothelial growth factor (anti-VEGF) antibodies that inhibit ocular neovascularisation, improve oedema and maintain visual acuity.

Brief item: Sensipar (cinacalcet) PBS listing to be deleted

From 1 August 2015 the calcimimetic therapy cinacalcet will be deleted from the list of drugs subsidised on the PBS

Brief item: Aripiprazole modified release (Abilify Maintena) for schizophrenia

A full NPS RADAR review of aripiprazole oral was published in May 2004. This In Brief extends the evidence presented in that review to the new long-acting injection (LAI) formulation and compares safety and efficacy against oral aripiprazole and other LAI antipsychotics.